The Present and Future of Measurable Residual Disease Testing in Acute Myeloid Leukemia

Researchers review the current approaches to measurable residual disease (MRD) testing in AML, discuss strengths and limitations, highlight recent technological advances that may improve such testing, and summarize ongoing initiatives to generate the clinical evidence needed to advance the use of MRD testing in patients with AML.